If they ever successfully design and complete a phase 2 trial on their own, with positive results, I will change my tune. Or, if they sign a blockbuster licensing deal for 289 or another compound that provides enough cash to avoid the next round of dilution, I will send DJ flowers.
It seems to be moving with the market x Beta to me. Nothing special happening at present. Keep an eye on the options. If it breaks past $25 on volume and we see some option volume, then it might be time to get excited. IMO, not advice.
I own other stocks, but none quite as disappointing and poorly managed considering the potential, technology, SGEN relative performance, etc. One day this will pay off (I think).
They hired another money-sucking executive that has nothing to do with advancing the pipeline, developing new drugs, etc. Maybe she will search for a new CEO, or fire some of the dead wood...not.
I really appreciate the manufactured dips. Now it's about time for you to exit! As my dad used to say, don't let the door hit you in the rear on the way out.
not sure anything short of an acquisition will get Immunoslug over $17-18. SGEN and now ECYT are kicking their asres.
Yes, hello we all said they had to step it up, we all believed that the drugs works. It's good to see the media and some slow sell-side analysts are finally catching on. Apparently ARNA shorts are even slower than media and sell-side, with the exception of the few who have been positive like Thomas Wei.
The timing of this oral CHMP presentation looks strange. If they have more data available in March, why not wait for the additional data and then present? Are the data same drug and same indication/disease?
I find the Jan 2015 open call interest much more significant and interesting. 45,000 $15 strike, 15,000 $12 strike, 14,000 $35 strike. Playing with Feb calls with 3 days remaining is a #$%$ shoot/wild #$%$ speculation.
It's fairly obvious, Eisai will have the right of refusal, first opportunity to move and it's also obvious that ARNA is not interested in selling now because the price is too low. When sales increase and the price rises to double digits, we can revisit this topic. For now, nothing is going to happen. The other factor is the pipeline. ARNA could develop another significant product and that would change everything, expand their options in terms of a potential acquirer, multiple acquirers, going alone, selling off one product and keeping others...
Disagree, I don't have an opinion on the stock, but if I thought the trial would be successful and liked it before, this is a buying opportunity. If I thought the company was a sham, nothing has changed. This is a typical biotech sell side analyst chicken shyte call. Mara apparently can't think for herself and has apparently not been doing strong DD.
these clauses are very common to prevent hostile acquisitions. Since many SGEN employees are from Roche, don't rule them out. I hope someone buys them, so people turn their attention to IMGN as the next target. Let the bidding begin, they should both be acquired!
I can agree with this, but not with those calling for a bodily harm.
I have been long ACAD since $2 and I don't recall him being negative. He has been against ARNA until recently, apparently he flipped finally. ARNA shorts have created many great buying opportunities and a low stock price for accumulation. When there's a large short position, shorts are talking their book with him and he listens and generally follows, or shares their advice with readers. Sometimes shorts are right (shorts have vast resources, employ smart people, look for an edge in clinical trial info, they do their own market research...) and sometimes they still get it wrong (ARNA). Place your bets and take responsibility for your own decisions.
AF thinks vaccines don't work and until more of them do, he is probably going to continue with his opinion. CELG (GVAX) was another failure where I was on the opposite side and lost. I still think that GVAX would work in the right hands, the issue was a management failure.
I have been investing in biotech for 25 years and don't rely on anyone including AF and in fact, I frequently oppose his investment advice (ARNA, IMGN more). If you invest in biotech long enough you will have failures and hopefully some winners. In 2012 I made 125% and last year 65%. This YTD I am up about 5%.
This one could go either way, but it's not something I would bet on at this moment (my opinion, not advice). I am focused on other stocks and not really interested in GALE, so I have not done the DD. Good luck.
crime is for a court to decide. I was long GNTA several years ago, AF tried to warn GNTA longs. I and many others who did not listen to him lost a bundle. In biotech no one has a 100% track record. Do your own DD and don't blame others if you make a mistake and don't drag ARNA and their shareholders into your problems.